Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
Antimicrob Agents Chemother
; 58(12): 7565-9, 2014 Dec.
Article
in En
| MEDLINE
| ID: mdl-25267674
ABSTRACT
Here, we evaluated the in vitro anti-HIV-1 activity of the experimental CCR5 inhibitor VCH-286 as a single agent or in combination with various classes of HIV-1 inhibitors. Although VCH-286 used alone had highly inhibitory activity, paired combinations with different drug classes led to synergistic or additive interactions. However, combinations with other CCR5 inhibitors led to effects ranging from synergy to antagonism. We suggest that caution should be exercised when combining CCR5 inhibitors in vivo.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperazines
/
Pyrimidines
/
Spiro Compounds
/
Triazoles
/
Tropanes
/
HIV-1
/
Reverse Transcriptase Inhibitors
/
Anti-HIV Agents
/
Receptors, CCR5
/
Cyclohexanes
Limits:
Humans
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2014
Document type:
Article
Affiliation country:
Canada